Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in advanced cancer
NCT02038699Phase 2Withdrawn
- Sponsor
- Chimerix Inc.
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in glioblastoma multiforme (GBM), colorectal cancer (CRC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), sponsored by Chimerix Inc.. Planned start Jan 2014; status: withdrawn.
02
Drugs
dordaviprone
03
Conditions
glioblastoma multiforme (GBM)colorectal cancer (CRC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02038699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038699.